Cardiovascular Safety Pharmacology of Sibutramine

Cardiovascular Safety Pharmacology of Sibutramine

Sibutramine is an anorectic that has been banned since 2010 due to cardiovascular safety issues. However, counterfeit drugs or slimming products that include sibutramine are still available in the market. It has been reported that illegal sibutramine-contained pharmaceutical products induce cardiovascular crisis. However, the mechanism underlying sibutramine-induced cardiovascular adverse effec...

Clinical Pharmacology and Cardiovascular Safety of Naproxen

The voluntary withdrawal of Vioxx (rofecoxib) from the market in 2004, as well as the 2005 and 2014 US FDA Advisory Committee meetings about non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk, have raised questions surrounding the use of NSAIDs in at-risk populations. This paper discusses the cardiovascular safety profile of naproxen in the context of the NSAID class. The ba...

Sibutramine on Cardiovascular Outcome

S ibutramine, a combined norepinephrine and serotonin reuptake inhibitor, is effective in the management of obese patients requiring pharmacotherapy as part of a multimodal approach to weight loss. It improves insulin resistance markers, glucose metabolism, and atherogenic dyslipidemia in both diabetic and nondiabetic patients, most of these effects resulting fromweight loss. However, sibutrami...

Cardiovascular Safety Pharmacology using Collaborative Biosignal Analytics

ExEcutivE Summary Cardiotoxicity screening is in a state of flux. It is evident that screening for hERG block in immortalized cell lines and QT interval prolongation in animals as recommended by the ICH S7B guidelines is limited in predicting a drug's risk of causing the potentially fatal arrhythmia, Torsades de Pointes (TdP). The " Thorough QT study, " required by the FDA/ICH E14 safety guidel...

Educational package Cardiovascular Safety Pharm. Cardiovascular safety pharmacology in the minipig